ArticleJournal of comparative effectiveness research2015

Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Amer M Zeidan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.